Abstract
Systemic lupus erythematosus (SLE) is a multifactorial, autoimmune inflammatory disease with pleomorphic clinical manifestations involving different organs and tissues. The etiology of this disease has been associated with a dysfunctional response of B and T lymphocytes against environmental stimuli in individuals genetically susceptible to SLE, which determines an immune response against different autoantigens and, consequently, tissue damage. The study of different murine models has provided a better understanding of these autoimmune phenomena. This review primarily focuses on that has been learned from the pristane-induced lupus (PIL) model and how this model can be used to supplement recent advances in understanding the pathogenesis of SLE. We also consider both current and future therapies for this disease. The PubMed, SciELO, and Embase databases were searched for relevant articles published from 1950 to 2016. PIL has been shown to be a useful tool for understanding the multiple mechanisms involved in systemic autoimmunity. In addition, it can be considered an efficient model to evaluate the environmental contributions and interferon signatures present in patients with SLE.
Similar content being viewed by others
References
Arbuckle MR, McClain MT, Rubertone MV et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533. https://doi.org/10.1056/NEJMoa021933
Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939. https://doi.org/10.1056/NEJMra071297
Burlingame RW, Rubin RL (1991) Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 88:680–690. https://doi.org/10.1172/JCI115353
Griem P, Gleichmann E (1995) Metal ion induced autoimmunity. Curr Opin Immunol 7:831–838. https://doi.org/10.1016/0952-7915(95)80056-5
Woosley RL, Drayer DE, Reidenberg MM et al (1978) Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298:1157–1159. https://doi.org/10.1056/NEJM197805252982101
Satoh M, Reeves WH (1994) Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 180:2341–2346. https://doi.org/10.1084/jem.180.6.2341
Satoh M, Shaheen VM, Kao PN et al (1999) Autoantibodies define a family of proteins with conserved double- stranded RNA-binding domains as well as DNA binding activity. J Biol Chem 274:34598–34604. https://doi.org/10.1074/jbc.274.49.34598
Elkon KB, Bonfa E, Brot N (1992) Antiribosomal antibodies in systemic lupus erythematosus. Rheum Dis Clin N Am 18:377–390
Hamilton KJ, Satoh M, Swartz J et al (1998) Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. Clin Immunol Immunopathol 86:271–279
Reeves WH, Lee PY, Weinstein JS et al (2010) Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 30:455–464. https://doi.org/10.1016/j.it.2009.06.003.Induction
Avigan J, Blumer M (1968) On the origin of pristane in marine organisms. J Lipid Res 9:350–352
Potter M, Wax JS (1981) Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol 127:1591–1595
Satoh M, Kumar A, Kanwar YS, Reeves WH (1995) Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci 92:10934–10938. https://doi.org/10.1073/pnas.92.24.10934
Janz S, Shacter E (1991) A new method for delivering alkanes to mammalian cells: preparation and preliminary characterization of an inclusion complex between beta-cyclodextrin and pristane (2,6,10,14-tetramethylpentadecane). Toxicology 69:301–315
White S, Rosen A (2003) Apoptosis in systemic lupus erythematosus. Curr Opin Rheumatol 15:557–562
Calvani N, Caricchio R, Tucci M et al (2005) Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. J Immunol 175:4777–4782
Nacionales DC, Kelly-Scumpia KM, Lee PY et al (2007) Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 56:3770–3783. https://doi.org/10.1002/art.23023
Mitani Y, Takaoka A, Kim SH et al (2001) Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 6:631–640
Richards HB, Satoh M, Jennette JC et al (2001) Interferon-γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 60:2173–2180. https://doi.org/10.1046/j.1523-1755.2001.00045.x
Richards HB, Satoh M, Shaw M et al (1998) Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 188:985–990. https://doi.org/10.1084/jem.188.5.985
Calvani N, Satoh M, Croker BP et al (2003) Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. Kidney Int 64:897–905. https://doi.org/10.1046/j.1523-1755.2003.00178.x
MAGRAM J, SFARRA J, CONNAUGHTON S et al (1996) IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. Ann N Y Acad Sci 795:60–70. https://doi.org/10.1111/j.1749-6632.1996.tb52655.x
Okamura H, Tsutsui H, Komatsu T et al (1995) Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88–91. https://doi.org/10.1038/378088a0
Smeltz RB, Chen J, Hu-Li J, Shevach EM (2001) Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1/Th2 differentiation. Critical downregulatory role of IL-4. J Exp Med 194:143–153
Baechler EC, Batliwalla FM, Karypis G et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci 100:2610–2615. https://doi.org/10.1073/pnas.0337679100
Bennett L, Palucka AK, Arce E et al (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197:711–723. https://doi.org/10.1084/jem.20021553
Zhuang H, Narain S, Sobel E et al (2005) Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol 117:238–250. https://doi.org/10.1016/j.clim.2005.07.009
Feng X, Wu H, Grossman JM et al (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54:2951–2962. https://doi.org/10.1002/art.22044
Kirou KA, Lee C, George S et al (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52:1491–1503. https://doi.org/10.1002/art.21031
Pascual V, Farkas L, Banchereau J (2006) Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 18:676–682. https://doi.org/10.1016/j.coi.2006.09.014
Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25:383–392. https://doi.org/10.1016/j.immuni.2006.08.010
Nacionales DC, Kelly KM, Lee PY et al (2006) Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol 168:1227–1240. https://doi.org/10.2353/ajpath.2006.050125
Thibault DL, Graham KL, Lee LY et al (2009) Type I interferon receptor controls B-cell expression of nucleic acid-sensing toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res Ther 11:R112. https://doi.org/10.1186/ar2771
Lee PY, Weinstein JS, Nacionales DC et al (2008) A novel type I IFN-producing cell subset in murine lupus. J Immunol 180:5101–5108
Båve U, Magnusson M, Eloranta M-L et al (2003) Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 171:3296–3302
Swirski FK, Libby P, Aikawa E et al (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117:195–205. https://doi.org/10.1172/JCI29950
Kawai T, Akira S (2006) Innate immune recognition of viral infection. Nat Immunol 7:131–137. https://doi.org/10.1038/ni1303
Means TK, Latz E, Hayashi F et al (2005) Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115:407–417. https://doi.org/10.1172/JCI23025
Savarese E (2006) U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107:3229–3234. https://doi.org/10.1182/blood-2005-07-2650
Vollmer J, Tluk S, Schmitz C et al (2005) Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves toll-like receptors 7 and 8. J Exp Med 202:1575–1585. https://doi.org/10.1084/jem.20051696
Gilliet M, Cao W, Liu Y-J (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8:594–606. https://doi.org/10.1038/nri2358
Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995. https://doi.org/10.1038/ni1112
Lee PY, Kumagai Y, Li Y et al (2008) TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 205:2995–3006. https://doi.org/10.1084/jem.20080462
Savarese E, Steinberg C, Pawar RD et al (2008) Requirement of toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 58:1107–1115. https://doi.org/10.1002/art.23407
Ewald SE, Barton GM (2011) Nucleic acid sensing toll-like receptors in autoimmunity. Curr Opin Immunol 23:3–9. https://doi.org/10.1016/j.coi.2010.11.006
Bly JE, Garrett LR, Cuchens MA (1990) Pristane induced changes in rat lymphocyte membrane fluidity. Cancer Biochem Biophys 11:145–154
Herrmann M, Voll RE, Zoller OM et al (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41:1241–1250. https://doi.org/10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H
Barrat FJ, Meeker T, Gregorio J et al (2005) Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 202:1131–1139. https://doi.org/10.1084/jem.20050914
Vallin H, Perers A, Alm GV, Rönnblom L (1999) Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 163:6306–6313
Clynes R, Calvani N, Croker BP, Richards HB (2005) Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors. Clin Exp Immunol 141:230–237. https://doi.org/10.1111/j.1365-2249.2005.02847.x
Bossaller L, Christ A, Pelka K et al (2016) TLR9 deficiency leads to accelerated renal disease and myeloid lineage abnormalities in pristane-induced murine lupus. J Immunol 197:1044–1053. https://doi.org/10.4049/jimmunol.1501943
Zhuang H, Han S, Li Y et al (2016) A novel mechanism for generating the interferon signature in lupus: opsonization of dead cells by complement and IgM. Arthritis Rheumatol 68:2917–2928. https://doi.org/10.1002/art.39781
Carlucci F, Ishaque A, Ling GS et al (2016) C1q modulates the response to TLR7 stimulation by pristane-primed macrophages: implications for pristane-induced lupus. J Immunol 196:1488–1494. https://doi.org/10.4049/jimmunol.1401009
Smith S, Fernando T, Wu PW et al (2017) MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. J Autoimmun 79:105–111. https://doi.org/10.1016/j.jaut.2017.03.003
Tan EM (1989) Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93–151
Satoh M, Hamilton KJ, Ajmani AK et al (1996) Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane. J Immunol 157:3200–3206
Satoh M, Richards HB, Shaheen VM et al (2000) Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol 121:399–405. https://doi.org/10.1046/j.1365-2249.2000.01276.x
Satoh M, Treadwell EL, Reeves WH (1995) Pristane induces high titers of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice. Quantitation by antigen capture ELISAs based on monospecific human autoimmune sera. J Immunol Methods 182:51–62. https://doi.org/10.1016/0022-1759(95)00022-3
Wooley PH, Seibold JR, Whalen JD, Chapdelaine JM (1989) Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum 32:1022–1030
Christensen SR, Shupe J, Nickerson K et al (2006) Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25:417–428. https://doi.org/10.1016/j.immuni.2006.07.013
Christensen SR, Shlomchik MJ (2007) Regulation of lupus-related autoantibody production and clinical disease by toll-like receptors. Semin Immunol 19:11–23. https://doi.org/10.1016/j.smim.2006.12.005
Han S, Zhuang H, Xu Y et al (2015) Maintenance of autoantibody production in pristane-induced murine lupus. Arthritis Res Ther 17:384. https://doi.org/10.1186/s13075-015-0886-9
Lu A, Li H, Niu J et al (2017) Hyperactivation of the NLRP3 inflammasome in myeloid cells leads to severe organ damage in experimental lupus. J Immunol 198:1119–1129. https://doi.org/10.4049/jimmunol.1600659
Kahlenberg JM, Yalavarthi S, Zhao W et al (2014) An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheumatol 66:152–162. https://doi.org/10.1002/art.38225
Morse MD, Clark KL, Cascalho M, Kahlenberg JM (2016) Caspase-1 is required for maintenance of marginal zone B cells in pristane-induced lupus. Lupus 25:81–87. https://doi.org/10.1177/0961203315606982
Mizutani A, Shaheen VM, Yoshida H et al (2005) Pristane-induced autoimmunity in germ-free mice. Clin Immunol 114:110–118. https://doi.org/10.1016/j.clim.2004.09.010
Richards, Satoh, Jennette et al (1999) Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin Exp Immunol 115:547–553. https://doi.org/10.1046/j.1365-2249.1999.00825.x
Nacionales DC, Weinstein JS, Yan X-J et al (2009) B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus. J Immunol 182:4226–4236. https://doi.org/10.4049/jimmunol.0800771
Levitt NG, Fernandez-Madrid F, Wooley PH (1992) Pristane induced arthritis in mice. IV Immunotherapy with monoclonal antibodies directed against lymphocyte subsets. J Rheumatol 19:1342–1347
Kratz A, Campos-Neto A, Hanson MS, Ruddle NH (1996) Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 183:1461–1472
Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6:205–217. https://doi.org/10.1038/nri1786
Jego G, Palucka AK, Blanck J-P et al (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225–234
Sverdrup B, Källberg H, Bengtsson C et al (2005) Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study. Arthritis Res Ther 7:R1296–303. https://doi.org/10.1186/ar1824
Dahlgren J, Takhar H, Anderson-Mahoney P et al (2007) Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional study. Environ Health 6:8. https://doi.org/10.1186/1476-069X-6-8
Kuroda Y, Nacionales DC, Akaogi J et al (2004) Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 58:325–337. https://doi.org/10.1016/j.biopha.2004.04.009
Smith DL, Dong X, Du S et al (2007) A female preponderance for chemically induced lupus in SJL/J mice. Clin Immunol 122:101–107. https://doi.org/10.1016/j.clim.2006.09.009
Pistiner M, Wallace DJ, Nessim S et al (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21:55–64. https://doi.org/10.1016/0049-0172(91)90057-7
Chowdhary VR, Grande JP, Luthra HS, David CS (2007) Characterization of haemorrhagic pulmonary capillaritis: another manifestation of pristane-induced lupus. Rheumatology 46:1405–1410. https://doi.org/10.1093/rheumatology/kem117
Koffler D, Agnello V, Thoburn R, Kunkel HG (1971) Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med 134:169–179
Kulkarni O, Pawar RD, Purschke W et al (2007) Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 18:2350–2358. https://doi.org/10.1681/ASN.2006121348
Zhuang H, Han S, Xu Y et al (2014) Toll-like receptor 7-stimulated tumor necrosis factor alpha causes bone marrow damage in systemic lupus erythematosus. Arthritis Rheumatol 66:140–151. https://doi.org/10.1002/art.38189
Chen X, Cui L, Li R et al (2016) Development of pristane induced mice model for lupus with atherosclerosis and analysis of TLR expression. Clin Exp Rheumatol 34:600–608
Kamen DL, Strange C (2010) Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 31:479–488. https://doi.org/10.1016/j.ccm.2010.05.001
Zamora MR, Warner ML, Tuder R, Schwarz MI (1997) Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 76:192–202
Satoh M, Weintraub JP, Yoshida H et al (2000) Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus. J Immunol 165:1036–1043
Barker T, Lee P, Kelly-Scumpia K et al (2011) Pathogenic role of B cells in the development of diffuse alveolar hemorrhage induced by pristane. Lab Investig 91:1540–1550. https://doi.org/10.1038/labinvest.2011.108
Zhuang H, Han S, Lee PY et al (2017) Pathogenesis of diffuse alveolar hemorrhage in murine lupus. Arthritis Rheumatol 69:1280–1293. https://doi.org/10.1002/art.40077
Fernandez S, Jose P, Avdiushko MG et al (2004) Inhibition of IL-10 receptor function in alveolar macrophages by toll-like receptor agonists. J Immunol 172:2613–2620. https://doi.org/10.4049/jimmunol.172.4.2613
Hussell T, Bell TJ (2014) Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 14:81–93. https://doi.org/10.1038/nri3600
Murray PJ, Smale ST (2012) Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat Immunol 13:916–924. https://doi.org/10.1038/ni.2391
Ioannou Y, Isenberg DA (2000) Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431–1442. https://doi.org/10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
Rönnblom LE, Alm GV, Oberg KE (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115:178–183
Zhou L, Wei W, Si J, Yuan D (2010) Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice. Mediat Inflamm 2010:1–7. https://doi.org/10.1155/2010/951210
Minhas U, Minz R, Das P, Bhatnagar A (2012) Therapeutic effect of Withania somnifera on pristane-induced model of SLE. Inflammopharmacology 20:195–205. https://doi.org/10.1007/s10787-011-0102-8
Pervaiz S (2003) Resveratrol: from grapevines to mammalian biology. FASEB J 17:1975–1985. https://doi.org/10.1096/fj.03-0168rev
Wang Z-L, Luo X-F, Li M-T et al (2014) Resveratrol possesses protective effects in a pristane-induced lupus mouse model. PLoS One 9:e114792. https://doi.org/10.1371/journal.pone.0114792
Li M, Shi X, Qian T et al (2015) A20 overexpression alleviates pristine-induced lupus nephritis by inhibiting the NF-κB and NLRP3 inflammasome activation in macrophages of mice. Int J Clin Exp Med 8:17430–17440
Opipari AW, Boguski MS, Dixit VM (1990) The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 265:14705–14708
Bender AT, Pereira A, Fu K et al (2016) Btk inhibition treats TLR7/IFN driven murine lupus. Clin Immunol 164:65–77. https://doi.org/10.1016/j.clim.2016.01.012
Zhang D, Liu R, Sun L et al (2011) Anti-inflammatory activity of methyl salicylate glycosides isolated from Gaultheria yunnanensis (Franch.) Rehder. Molecules 16:3875–3884. https://doi.org/10.3390/molecules16053875
He Y-Y, Yan Y, Zhang H-F et al (2016) Methyl salicylate 2-O-β-d-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction. Drug Des Devel Ther 10:3183–3196. https://doi.org/10.2147/DDDT.S114501
Lin Y, Yan Y, Zhang H et al (2017) Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice. Acta Pharm Sin B 7:159–166. https://doi.org/10.1016/j.apsb.2016.07.001
Lim LHK, Pervaiz S (2007) Annexin 1: the new face of an old molecule. FASEB J 21:968–975. https://doi.org/10.1096/fj.06-7464rev
Mihaylova N, Bradyanova S, Chipinski P, et al (2017) Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. Autoimmunity 0:1–12. doi: https://doi.org/10.1080/08916934.2017.1300884
Financial support
Funding for this study was provided by the Research and Event Incentive Fund (FIPE-HCPA).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
None.
Rights and permissions
About this article
Cite this article
Freitas, E.C., de Oliveira, M.S. & Monticielo, O.A. Pristane-induced lupus: considerations on this experimental model. Clin Rheumatol 36, 2403–2414 (2017). https://doi.org/10.1007/s10067-017-3811-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3811-6